Investors Title Company reported a strong Q2 with premiums rising over 30% quarter-on-quarter, leading to a 19% increase in earnings per share to $7.73. This growth is driven by increased US residential real estate transactions, benefiting from robust margins and low claim rates. The company’s earnings are sensitive to housing market trends and interest rates, which can affect transaction volumes and investment income. While the stock is viewed as an attractive option on housing market activity, the current recommendation is to hold rather than buy, awaiting clearer signals for initiating a position.
Neurocrine Biosciences is rated a 'Buy' due to its robust cash flows, strong product launches, and a diversified drug pipeline. Its main revenue driver, Ingrezza, holds exclusivity until 2038 with projected peak sales of $3.3 billion. Additional prod...
MUBARAK token price jumped 26.1% to $0.0266 with daily trading volume reaching $42.36 million, driven by a $200,000 BNB Chain campaign promoting meme tokens. Other BNB Chain tokens like BinanceLife, TUT, and Hajimi also saw double-digit gains. The ca...
When leaving Austria with significant Bitcoin holdings, the country may impose an exit tax calculated as if the Bitcoin were sold at the moment of departure, based on the market value then. If moving to an EU or EEA country, tax payment can be deferr...
Stanley Druckenmiller invested $64.7 million in Bitdeer, a bitcoin mining and data center operator, and $23.1 million in Hyperliquid Strategies, a decentralized trading platform, during Q2 2026. These moves reflect his growing interest in digital ass...
U.S.-listed spot Bitcoin and Ether ETFs attracted a combined $2.61 billion over five trading sessions, marking their strongest weekly inflows since October 2025. Bitcoin ETFs led with $1.92 billion, making up 73% of the total, while Ether ETFs added ...
